Skip to content
cardio.webdr
ToolsSpecialtiesEchoHeart sounds
ToolsSpecialtiesEchoHeart soundsFavoritesPrivate notes
cardio.webdr

Clinical clarity, in seconds. Built for focused decisions—not data collection.

Patient inputs stay on this device.
ExploreAll toolsSpecialtiesEchocardiographyHeart sounds
Your workspaceFavoritesPrivate notesCalculation historyOffline access
PlatformAboutFAQDevelopersFeedbackContact
© 2026 CardioWebdr Clinical support, not a substitute for judgment.PrivacyTermsStorageSupportReport an issue
All tools/Cardio-Oncology Scores
Interactive worksheet3 clinical inputsPatient data not stored

CHOP/Anthracycline Cumulative Dose Score Calculator

CHOP/Anthracycline Cumulative Dose Score: Explanation and Clinical Context The CHOP/Anthracycline Cumulative Dose Score estimates the risk of anthracycline-induced cardiotoxicity by calculating the total doxorubicin-equivalent dose from different anthracycline drugs, including doxorubicin, daunorubicin, and epirubicin. Conversion factors are applied to account for differences in cardiotoxic potential: daunorubicin ×

Interactive worksheet

Clinical inputs

0/3 filled
Inputs stay on this device
Active structured worksheetActive local worksheet: mapped inputs can be completed, validated, copied, saved, and exported on this device. No numerical score is asserted unless its formula is independently reproducible.
Clinical contextWhy this tool matters and how to interpret it

Understand the result,
not just the number.

CHOP/Anthracycline Cumulative Dose Score: Explanation and Clinical Context The CHOP/Anthracycline Cumulative Dose Score estimates the risk of anthracycline-induced cardiotoxicity by calculating the total doxorubicin-equivalent dose from different anthracycline drugs, including doxorubicin, daunorubicin, and epirubicin. Conversion factors are applied to account for differences in cardiotoxic potential: daunorubicin × 0.833 and epirubicin × 0.5 to obtain doxorubicin-equivalent doses. Risk stratification is based on cumulative dose thresholds: <250 mg/m² (low risk), 250–400 mg/m² (moderate risk), >400 mg/m² (high risk).

This tool helps clinicians anticipate cardiotoxicity risk, plan cardiac monitoring, and adjust chemotherapy dosing.

Evidence & references1 primary source mapped
  1. Source 1

    Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879. doi:10.1002/cncr.11407

Clinical discussionModerated, tool-specific conversation

Loading discussion…

Moderated before publishingNever include patient identifiers.

Workspace mode

Structured worksheet

Active local worksheet: mapped inputs can be completed, validated, copied, saved, and exported on this device. No numerical score is asserted unless its formula is independently reproducible.

On this pageWorksheet Clinical context References Discussion

Privacy by default

Inputs, results, favorites, and notes remain in your browser unless you explicitly export them.

Privacy details
Report formula or content issue
Continue exploring

Related clinical tools

More in this specialty
Interactive worksheet

LV GLS Drop >15% Calculator

Cardio-Oncology Scores
Interactive worksheet

Mean Heart Dose (MHD) Risk Predictor

Cardio-Oncology Scores
Interactive worksheet

Cleveland Clinic Anthracycline-Induced Heart Failure Risk Calculator

Cardio-Oncology Scores
Interactive worksheet

Immune Checkpoint Inhibitor Myocarditis Risk Index Calculator

Cardio-Oncology Scores
Clinical structure and calculation context point directly to Source 1; additional primary references remain listed for auditability.